TsokosGCMoutsopoulosHMSteinbertAD. Muscle involvement in systemic lupus erythematosus. JAMA1981; 246: 766–768.
2.
ZomaA. Musculoskeletal involvement in systemic lupus erythematosus. Lupus2004; 13: 851–853.
3.
KaldenPKrauseTVolkBPeterHHvon KempisJ. Myositis of small foot muscles. Rheumatol Int1998; 18: 79–82.
4.
Ramos-CasalsMSotoMJCuadradoMJKhamashtaMA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus2009; 18: 767–776.
5.
LuTYNgKPCambridgeG. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum2009; 61: 482–487.
6.
Rios FernandezRCallejas RubioJLSánchez CanoDSáez MorenoJAOrtego CentenoN. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies: a report of 4 cases and review of the literature. Clin Exp Rheumatol2009; 27: 1009–1016.
7.
MajmudarSHallHAZimmermannB. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol2009; 15: 338–340.
8.
Ramos-CasalsMGarcia-HernandezFJDe RamonE. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol2010; 28: 468–476.